New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
11:42 EDTAMAGAMAG sees FY13 revenue $73M- $77M, consensus $79.12M
AMAG sees Feraheme U.S. net product revenues of between $63M-$67M, driven by a combination of price and double-digit volume growth; Royalties and product sales related to ex-U.S. sales of Feraheme/Rienso and recognition of milestones of approximately $10M.
News For AMAG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 28, 2015
07:54 EDTAMAGAMAG Pharmaceuticals management to meet with Maxim
Subscribe for More Information
September 25, 2015
06:24 EDTAMAGLeerink says AMAG 'extremely attractive' after McGuff label disclosure
Subscribe for More Information
06:04 EDTAMAGAMAG obtained package insert for McGuff's Hydroxyprogesterone Caproate
AMAG Pharmaceuticals disclosed last night that following the recent approval by the FDA of the abbreviated new drug application for Hydroxyprogesterone Caproate Injection, initially submitted by McGuff Pharmaceuticals in 2009, the company obtained, through a Freedom of Information Act request, the package insert for the product. Reference Link
September 24, 2015
15:27 EDTAMAGRaymond James expects AMAG Pharmaceuticals shares to rebound sharply
Subscribe for More Information
15:13 EDTAMAGAMAG Pharmaceuticals defended again at Raymond James
12:52 EDTAMAGAMAG Pharmaceuticals selloff unwarranted, says Raymond James
Subscribe for More Information
September 23, 2015
06:29 EDTAMAGOrphan drug pricing concerns overdone, says Leerink
Leerink analyst Joseph Schwartz says his firm's Orphan Drug Payor survey contrasts with the recent bearish investor sentiment over the orphan drug business model. The survey of 30 payors indicates that the reimbursement landscape "remains highly favorable" for commercially insured patients and is able to withstand potential weakness caused by proposed changes to Medicare pricing, Schwartz tells investors in a research note. His analysis suggests a "surprisingly limited" impact to valuations of orphan drug companies should Medicare patients receive drug discounts. Schwartz views the pricing concerns stemming from Hillary Clinton's plan to combat high drug prices as overdone. He reiterates Outperform ratings on AMAG Pharmaceuticals (AMAG), BioMarin (BMRN), Raptor Pharmaceuticals (RPTP) and Retrophin (RTRX).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use